Poseida Therapeutics (United States)

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Immunology and Microbiology 12.7×
• Biochemistry, Genetics and Molecular Biology 7.0×
• Medicine 2.5×
• Chemistry 0.3×
• Engineering 0.2×

By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, Tumor Regression, Lymphoma, CAR T Cells, Chimeric Antigen Receptor, Gene Therapy and Genome Engineering.

By volume in 2022–2025: CAR-T cell therapy research, CRISPR and Genetic Engineering, Biosimilars and Bioanalytical Methods and Virus-based gene therapy research.

1. 1 CAR-T cell therapy research Oncology 4 works
2. 2 CRISPR and Genetic Engineering Molecular Biology 1 works
3. 3 Biosimilars and Bioanalytical Methods Immunology 1 works
4. 4 Virus-based gene therapy research Genetics 1 works
5. 5 RNA Interference and Gene Delivery Molecular Biology 1 works
6. 6 Multiple Myeloma Research and Treatments Hematology 1 works
7. 7 Hemophilia Treatment and Research Hematology 1 works
8. 8 Cancer Research and Treatments Biotechnology 0 works
9. 9 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
10. 10 Immunotherapy and Immune Responses Immunology 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 60% higher than in 2013–2017.

• University of California San Diego
• San Diego State University
• Scripps Research Institute
• University of San Diego
• University of California San Diego Medical Center
• General Atomics (United States)
• Scripps Health
• Naval Medical Center San Diego